HAE Treatment Options

WAO/EAACI 2021 Guidelines: Select Recommendations in Adults

In 2022, the World Allergy Organization (WAO) in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI) published an update and revision to their global guideline for HAE. An international expert panel was convened to review the existing evidence and developed recommendations with the goal of providing clinicians and their patients with guidance that will assist them in making rational decisions in the management of Type 1 and Type 2 HAE. Read the full Guideline.

On-Demand Treatment: All Attacks Are Considered for On-demand Treatment

Early treatment with C1-INH concentrate, ecallantide, or Icatibant Injection provides a better treatment response than late treatment. Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity. As early treatment is facilitated by self-administration, all patients with HAE Types 1 or 2 should be considered for home therapy and self-administration training. All C1-INH concentrates and icatibant are licensed for self-administration, although approved product indications vary around the world.8 It is recommended that all patients have sufficient medication for on-demand treatment of two attacks and carry on-demand medication at all times.

Why Switch to Generic Icatibant Injection?

Fresenius Kabi’s generic Icatibant Injection is an FDA-approved, fully substitutable equivalent to Firazyr®*

  • It’s convenient
  • It’s less expensive
  • It’s safe
  • It’s effective
  • It’s from a trustworthy company that uses quality ingredients

Why Trust Fresenius Kabi Generics?

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, clinical nutrition, and specialty pharmaceuticals.

Our products and programs are designed to help care for critically and chronically ill patients.


  • [8] Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990.